Brief: Burning Rock Receives CE Mark For Its Overc™ Multi-Cancer Detection Blood Test Kit
01/06/2022 12:52
June 1 (Reuters) - Burning Rock Biotech Ltd BNR.O :
* BURNING ROCK RECEIVES CE MARK FOR ITS OVERC™ MULTI-CANCER
DETECTION BLOOD TEST KIT
Source text for Eikon: ID:nPn80WBQga
Further company coverage: BNR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Burning Rock Biotech
See all newsBurning Rock Biotech's Q2 revenue falls, net loss widens on central laboratory weakness
China's Burning Rock Biotech Q1 revenue falls on lower test volumes
China's Burning Rock Biotech Q4 net loss narrows as costs fall
Cancer diagnostics firm Burning Rock Biotech's Q3 revenue rises on pharma R&D growth
Brief: Burning Rock's Oncoguide™ Oncoscreen™ Plus CDX System Now Approved In Japan As A Companion Diagnostic For Capivasertib In Breast Cancer